Clinical Trial Update: PSMA-Targeted Intraoperative Fluorescent Imaging Agents (DGPR1008): Validation Across Different Time Windows [Phase 2]

View source ↗

Summary

Phase 2 trial update on validating DGPR1008, a PSMA-targeted intraoperative fluorescent imaging agent, across different time windows in prostate cancer patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DGPR1008

Snippet

Sponsor: Haitao Niu, MD | Conditions: Prostate Cancer Patients Undergoing Radical Prostatectomy | Phase 2 | Status: NOT_YET_RECRUITING